Differential cytogenomics and miRNA signature of the acute myeloid leukaemia Kasumi-1 cell line CD34+38- compartment

Leukemia Research

Volumn 34, Issue 10, 2010, Pages 1287-1295

  Pedranzini, Laura ^a   Mottadelli, Federica ^a   Ronzoni, Simona ^b   Rossella, Franca ^a   Ferracin, Manuela ^c   Magnani, Ivana ^a   Roversi, Gaia ^a,d   Colapietro, Patrizia ^a   Negrini, Massimo ^c   Pelicci, Pier Giuseppe ^b   Larizza, Lidia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

AML; CD34+CD38 ; Cytogenomic characterization; Kasumi 1; MiRNA expression

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; DNA; MICRORNA; MICRORNA 182; MICRORNA 584; RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BIOINFORMATICS; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, CD34; ANTIGENS, CD38; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 4; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 77955980855     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.02.012     Document Type: Article

References (46)

1. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
2. Buzzeo M.P., Scott E.W., Cogle C.R. The hunt for cancer-initiating cells: a history stemming from leukemia. Leukemia 2007, 21:1619-1627.
3. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
4. Zucchi I., Sanzone S., Astigiano S., et al. The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci USA 2007, 104:10476-10481.
5. Kondo T., Setoguchi T., Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004, 101:781-786.
6. Peterson L.F., Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 2004, 23:4255-4262.
7. Gelmetti V., Zhang J., Fanelli M., et al. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998, 18:7185-7191.
8. Beghini A., Magnani I., Ripamonti C.B., et al. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J 2002, 3:157-163.
9. Kelly L.M., Gilliland D.G. Genetics of myeloid leukemias. Annu Rev Genom Hum Genet 2002, 3:179-198.
10. Asou H., Tashiro S., Hamamoto K., et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991, 77:2031-2036.
11. Rossi M.R., Laduca J., Cowell J.K., et al. Genomic analysis of CD8+ NK/T cell line, 'SRIK-NKL', with array-based CGH (aCGH), SKY/FISH and molecular mapping. Leuk Res 2008, 32:455-463.
12. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
13. Horsley S.W., Mackay A., Iravani M., et al. Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss. Genes Chromosomes Cancer 2006, 45:554-564.
14. Rucker F.G., Sander S., Dohner K., et al. Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations. Leukemia 2006, 20:994-1001.
15. Larizza L., Magnani I., Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005, 46:247-255.
16. Mangino M., Brouilette S., Braund P., et al. A regulatory SNP of the BICD1 gene contributes to telomere length variation in humans. Hum Mol Genet 2008, 17:2518-2523.
17. Chan W.I., Huntly B.J. Leukemia stem cells in acute myeloid leukemia. Semin Oncol 2008, 35:326-335.
18. Nishii K., Usui E., Katayama N., et al. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia 2003, 17:731-737.
19. Beghini A., Larizza L., Cairoli R., et al. c-kit activating mutations and mast cell proliferation in human leukemia. Blood 1998, 92:701-702.
20. Beghini A., Ripamonti C.B., Cairoli R., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004, 89:920-925.
21. Beghini A., Ripamonti C.B., Castorina P., et al. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement. Cancer Genet Cytogenet 2000, 119:26-31.
22. Beghini A., Tibiletti M.G., Roversi G., et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001, 92:657-662.
23. Dias S., Hattori K., Zhu Z., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000, 106:511-521.
24. Gerber H.P., Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003, 81:20-31.
25. Imai N., Miwa H., Shikami M., et al. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor. Leuk Res 2009, 33:1650-1657.
26. Imai N., Shikami M., Miwa H., et al. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. Br J Haematol 2006, 135:673-682.
27. Rothlisberger B., Heizmann M., Bargetzi M.J., et al. TRIB1 overexpression in acute myeloid leukemia. Cancer Genet Cytogenet 2007, 176:58-60.
28. Czepulkowski B., Powell A.R., Pagliuca A., et al. Trisomy 10 and acute myeloid leukemia. Cancer Genet Cytogenet 2002, 134:81-83.
29. Uckan D., Hicsonmez G., Yetgin S., et al. CD34/CD117 co-expression in childhood acute leukemia. Leuk Res 2000, 24:201-206.
30. Rytting M.E. Pediatric myelodysplastic syndromes. Curr Hematol Rep 2004, 3:173-177.
31. Tavil B., Cetin M., Tuncer M. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome. Leuk Res 2006, 30:222-224.
32. Bolufer P., Barragan E., Collado M., et al. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res 2006, 30:1471-1491.
33. Lee H.S., Lee J.H., Hur E.H., et al. Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. Leuk Res 2009, 33:426-433.
34. Blair A., Hogge D.E., Sutherland H.J. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood 1998, 92:4325-4335.
35. Shlien A., Malkin D. Copy number variations and cancer susceptibility. Curr Opin Oncol 2010, 22:55-63.
36. Guled M., Lahti L., Lindholm P.M., et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer 2009, 48:615-623.
37. Guttilla I.K., White B.A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009, 284:23204-23216.
38. Schaefer A., Jung M., Mollenkopf H.J., et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010, 126(5):1166-1176.
39. Segura M.F., Hanniford D., Menendez S., et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 2009, 106:1814-1819.
40. Dixon-McIver A., East P., Mein C.A., et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 2008, 3:e2141.
41. Jankovic D., Gorello P., Liu T., et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. Blood 2008, 111:5672-5682.
42. Carron C., Pascal A., Djiane A., et al. Frizzled receptor dimerization is sufficient to activate the Wnt/beta-catenin pathway. J Cell Sci 2003, 116:2541-2550.
43. Brady M., Vlatkovic N., Boyd M.T. Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol 2005, 25:545-553.
44. Rau R., Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009, 27(4):171-181.
45. Horsley V Epigenetics, Wnt signaling, and stem cells: the Pygo2 connection. J Cell Biol 2009, 185:761-763.
46. Van Loo P.F., Bouwman P., Ling K.W., et al. Impaired hematopoiesis in mice lacking the transcription factor Sp3. Blood 2003, 102:858-866.